Back to Stakeholders
Research, Drug Development & Manufacturing
Research, Drug Development & ManufacturingCompany-Led Drug Development & CommercializationEarly-Stage Translational Research (Pre-Clinical)
Research, Drug Development & ManufacturingCompany-Led Drug Development & Commercialization
Lead program: Pre-clinical

PharmaDrugCSE: PHRX | OTC Pink: LMLLF

1 Drug Candidate

PharmaDrug is a Canadian specialty pharmaceutical company focused on the research and development of controlled substances and natural medicines. Through its Sairiyo Therapeutics subsidiary, the company is developing a DMT candidate with FDA Orphan Drug Designation for prevention of ischemia-reperfusion injury in organ transplants, and is also studying DMT for ophthalmic indications. PharmaDrug also distributes medical cannabis in the EU via PharmaDrug Production GmbH.

Development Programmes

1

DMT (Ischemia-Reperfusion / Organ Transplant)

DMT
Pre-clinicalinactive
Neurological Injury

Ischemia-reperfusion injury / organ transplantation

Programme Tracker

Neurological Injury

Primary: US (FDA)
Pre-clinicalinactive

Programme appears stalled since 2021 ODD grant; no clinical advancement reported; company pivoting to cepharanthine

Milestones

regulatory-designation

Completed

Actual: Apr 1, 2021

FDA grants first-ever Orphan Drug Designation for DMT (ischemia-reperfusion injury in organ transplantation)

Why it matters: Historic regulatory milestone — first ODD for any psychedelic compound. Targets DMT's sigma-1 receptor activity (not 5-HT2A psychedelic effect) to protect organs from ischemia-reperfusion damage. ODD provides 7-year market exclusivity and reduced filing fees.

Company milestone

Completed

Actual: Feb 1, 2023

Research collaboration with PharmaTher for DMT microneedle transdermal patch development

Why it matters: Transdermal delivery could enable controlled, sub-psychedelic DMT dosing for cytoprotective applications.

Company milestone

Completed

Actual: Jun 1, 2025

Board forms special committee for comprehensive strategic review; company pivoting toward cepharanthine (PD-001) and Canurta Biotech botanical drugs

Why it matters: Strategic review signals DMT programme has been deprioritized. PharmaDrug appears to be pivoting its clinical resources toward PD-001 (cepharanthine for viral diseases) via Sairiyo Therapeutics subsidiary and botanical neurodegeneration drugs via Canurta.

Recorded Events

Jun 1, 2025: Company milestone

Feb 1, 2023: Company milestone

Apr 1, 2021: regulatory-designation

Quick Facts

Type
Public Biotech
Ticker
CSE: PHRX | OTC Pink: LMLLF
Lead Stage
Pre-clinical
Website
Visit